Vaccitech (NASDAQ:VACC) Trading Down 4.2%

Vaccitech plc (NASDAQ:VACC)’s stock price dropped 4.2% during trading on Tuesday . The company traded as low as $2.51 and last traded at $2.53. Approximately 18,050 shares changed hands during trading, a decline of 93% from the average daily volume of 244,643 shares. The stock had previously closed at $2.64.

Vaccitech Price Performance

The company has a market cap of $97.52 million, a price-to-earnings ratio of -1.77 and a beta of -0.40. The business’s fifty day moving average price is $2.75 and its 200 day moving average price is $3.14.

Institutional Investors Weigh In On Vaccitech

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new stake in Vaccitech in the 1st quarter worth about $26,000. Citadel Advisors LLC purchased a new position in Vaccitech in the second quarter valued at about $31,000. Janney Montgomery Scott LLC purchased a new stake in shares of Vaccitech during the 3rd quarter valued at approximately $46,000. Millennium Management LLC lifted its stake in shares of Vaccitech by 32.8% during the 4th quarter. Millennium Management LLC now owns 40,388 shares of the company’s stock valued at $97,000 after buying an additional 9,967 shares in the last quarter. Finally, Baird Financial Group Inc. purchased a new stake in shares of Vaccitech during the 4th quarter valued at approximately $217,000. 26.13% of the stock is owned by institutional investors.

Vaccitech Company Profile

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.